Table 4.
Second primary cancers reported by patients treated on S0816
| S0816 therapy received | Type of second cancer | Salvage therapy for HL prior to second cancer | SCT prior to second cancer | Time from S0816 treatment to second cancer, y |
|---|---|---|---|---|
| eBEACOPP | Myelodysplastic syndrome | Y | N | 5.1 |
| eBEACOPP | Kidney | N | N | 2.9 |
| eBEACOPP | Melanoma | N | N | 5.0 |
| eBEACOPP | Non-HL | N | N | 1.1 |
| eBEACOPP | Cervical | N | N | 0.8 |
| eBEACOPP | Medullary thyroid | N | N | 5.2 |
| eBEACOPP | Basal cell carcinoma | N | N | 2.9 |
| ABVD | Kidney | N | N | 0.6 |
| ABVD | Melanoma | N | N | 3.9 |
| ABVD | Non-HL | N | N | 0.6 |
| ABVD | Bladder | N | N | 4.8 |
| ABVD | Prostate | N | N | 4.4 |
| ABVD | Squamous cell carcinoma | N | N | 5.2 |
N, no; Y, yes.